In vitro susceptibility testing of various Candida species to flucytosine-fluconazole and flucytosine-amphotericin B combinations;Evaluation de l'activité antifongique in vitro des associations flucytosine-fluconazole et flucytosine-amphotéricine B sur diverses especes de Candida

Journal de Mycologie Medicale

Volumn 12, Issue 4, 2002, Pages 157-162

  Bertout, S ^a   Lebecq, J C ^a   Bastide, J M ^a   Mallie M ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Amphotericin B. Fluconazole; Candida; Combinations Etest; Flucytosine; In vitro susceptibility testing

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; FLUCONAZOLE; FLUCYTOSINE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA KRUSEI; CANDIDA TROPICALIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; SCREENING TEST;

CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA TROPICALIS; FUNGI; ISSATCHENKIA ORIENTALIS;

EID: 0036916339     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Barchiesi F, Schimizzi AM, Najvar LK, et al. Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob Agents Chemother 2001;45:1355-9.
2. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72.
3. Espinel-Ingroff A, Pfaller M, Erwin ME, Jones RN. Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2 % glucose. J Clin Microbiol 1996;34:848-52.
4. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994;120: 932-44.
5. Ghannoum MA, LB Rice. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-17.
6. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MG, Denning DW. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994;34:659-68.
7. Lewis RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002;49:345-51.
8. Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy 2001;21:149S-164S.
9. Masia Canuto M, Gutierrez Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002;2:550-63.
10. Mallié M, Bastide JM. Les nouveaux antifongiques et leur stratégie de recherche. Revue Française des Laboratoires 2001;332:63-9.
11. Marichal P, Koymans L, Willemsens S, et al. Contribution of mutations in the cytochrome P450 14 alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999; 145:2701-13.
12. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M-27 A. Villanova, 1997: PA.
13. Neely MN, Ghannoum MA. The exciting future of antifungal therapy. Eur J Clin Microbiol Infect Dis 2000;19:897-914.
14. Odds FC, Van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998;42:282-8.
15. Perea S, Lopez-Ribot JL, Kirkpatrick WR, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001;45:2676-84.
16. Pfaller MA, Messer SA, Bolmstrom A. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn Microbiol Infect Dis 1998;32:223-7.
17. Pfaller MA, Messer SA, Bolmstrom A, Odds FC, Rex JH. Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 1996;34:1691-3.
18. Pfaller MA, Messer SA, Karlsson A, Bolmstrom A. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J Clin Microbiol 1998;36:2586-9.
19. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24:235-47.
20. Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995;39:2520-2.
21. Warnock DW, Johnson EM, Rogers TR. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy. J Antimicrob Chemother 1998;42:321-31.
22. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: Time-kill, checkerboard, and E test. Antimicrob Agents Chemother 1996;40:1914-8.
23. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382-402.